A Phase II Study of AZD2171 in Breast Cancer Stage IV (10006202)
Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
AZD2171 (cediranib maleate) may stop the growth of tumor cells by blocking some of the
enzymes needed for cell growth and by blocking blood flow to the tumor. This phase II trial
is studying how well AZD2171 works in treating patients with refractory stage IV breast
cancer